#94 – Lock, Stock, & Sterilize: Strategies to Optimize Antimicrobial Lock Therapy & Prevent/Treat Catheter-Related Bloodstream Infections
BreakpointsShow Notes
It's time to arm yourselves with all the resources on antimicrobial locks! Join our experts, Drs. Louise-Marie Oleksiuk (@CanRowPharm), Nasia Safdar (@NasiaSafdar), Joel Topf (@kidney_boy), and our wonderful host, Dr. Julie Justo (@julie_justo), to discuss the ins and outs of antimicrobial locks and how to implement them! Funding for this podcast was provided by CorMedix Inc
Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About X: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp
References
https://drive.google.com/file/d/1K0A4Bomhbcn7AZJ1JFOWW8EdEZq-aZcd/view?usp=sharing
https://drive.google.com/file/d/1PRoQzEKJ1c0pa1XFc4yasxsMhx2A1DFU/view?usp=sharing
Helpful antimicrobial lock review: Justo JA, Bookstaver PB. Infect Drug Resist. 2014 Dec 12;7:343-63. doi: 10.2147/IDR.S51388. PMID: 25548523.
LOCK IT-100 Trial: Agarwal AK, et al. Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1446-1455. doi: 10.2215/CJN.0000000000000278. PMID: 37678222.
Cochrane review: Arechabala MC, et al. Cochrane Database Syst Rev. 2018 Apr 3;4(4):CD010597. doi: 10.1002/14651858.CD010597.pub2. PMID: 29611180.
Cost-effectiveness of ethanol lock ppx with newer dehydrated alcohol product: Raghu VK, et al. JPEN J Parenter Enteral Nutr. 2022 Feb;46(2):324-329. doi: 10.1002/jpen.2130. PMID: 33908050.
Antimicrobial lock development/implementation in a pediatric hospital: Zembles TN, et al. Am J Health Syst Pharm. 2018 Mar 1;75(5):299-303. doi: 10.2146/ajhp161056. PMID: 29472511.
Dr. Topf’s tweet surveying the prevalence of antimicrobial lock use in dialysis units
CRBSIs in hemodialysis patients before and during the COVID-19 pandemic: Johansen KL, et al. Clin J Am Soc Nephrol. 2022 Mar;17(3):429-433. doi: 10.2215/CJN.11360821. PMID: 35110377.
Antiseptic barrier caps review and meta-analysis: Gillis VELM, et al. Am J Infect Control. 2023 Jul;51(7):827-835. doi: 10.1016/j.ajic.2022.09.005. PMID: 36116679.
Check out our podcast host, Pinecast. Start your own podcast for free with no credit card required. If you decide to upgrade, use coupon code r-7e7a98 for 40% off for 4 months, and support Breakpoints.
More from Breakpoints
Does oseltamivir harm critically ill patients with influenza? In this Breakpoints and Communicable collaboration, Erin McCreary and Josh Davis are joined by Steve Webb and Steve Tong to discuss the REMAP-CAP trial results that are challenging a long-standing intensive care practice. Together, they review the study design, key findings, and implications for clinical care, while highlighting the importance of randomized clinical trials in shaping evidence-based medicine. At the time of recording, the REMAP-CAP results were available as a preprint.
Dr. Prathit Kulkarni, lead author of a recent state-of-the-art review on acute and chronic bacterial prostatitis, joins host Dr. Erin McCreary to discuss this complex disease state. They walk through diagnosis, epidemiology, treatment, and more. You won’t want to miss this episode!
Gram-negative resistance is beautifully intricate, scientifically elegant, and very complex. Nothing is more exciting than the recently approved and bursting pipeline of beta-lactamase inhibitors. Listen to Drs. Sam Aitken and Christophe Le Terrier, along with host Dr. Erin McCreary, describe the nuanced enzymology and other antibacterial properties of beta-lactamase inhibitors. This episode also discusses the concepts of stand-alone inhibitors, resistance development, and more. If you want to learn more about sulbactam, clavulanic acid, tazobactam, avibactam, relebactam, vaborbactam, durlobactam, enmetazobactam, zidebactam, nacubactam, ledaborbactam, taniborbactam, and xeruborbactam – this episode is for you!